Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of C1 esterase inhibitor for acute hereditary angioedema attacks
CTR20233782Phase 3Active
- Sponsor
- China Resources Boya Bio-pharmaceutical Group
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of c1-esterase inhibitor in hereditary angioedema (HAE), sponsored by China Resources Boya Bio-pharmaceutical Group. Started Mar 2024; status: active.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on CTR20233782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233782.